Jun 16 2010
Oncodesign Biotechnology announced today that it has signed a licensing agreement with Janssen Pharmaceutica NV related to Janssen’s macrocyclic chemistry technology. Oncodesign will have exclusive access to this technology for six years.
The technology will be one of the cornerstones of Oncodesign's integrated drug discovery efforts, together with the in vitro and in vivo translational research capabilities in oncology already established at the company. Terms of the agreement were not disclosed but grant Oncodesign a license to use and develop the technology in its internal and partnered research programs.
"This technology is a perfect complement to our well recognized expertise and capabilities in oncology, and most notably to our translational in vivo and ex vivo pharmacology models based on low passage xenografts directly derived from patient tumour material, and allows us to present a unique translational discovery platform to our clients," said Philippe Genne, President and CEO of Oncodesign.
"Having access to highly potent and selective kinase inhibitors has the potential to transform the use of this therapeutic approach in oncology as well as other therapeutic areas," added Jan Hoflack, CSO of Oncodesign.
AI-powered MRI predicts outcomes in prostate cancer